Safety

Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data.

BACKGROUND

Diabetes mellitus-a chronic metabolic disorder associated with an increased risk of muscle atrophy-can significantly impact patients' quality of life and overall health outcomes. While antidiabetic medications are crucial for managing blood glucose levels, some have been linked to muscle-related adverse...

🗓️ 2026-04-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data.

Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

BACKGROUND

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

METHODS

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients...

🗓️ 2025-11-03
📰 Publication: Eclinicalmedicine
Read MoreEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

hUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.

Sarcopenia, a multifactorial syndrome characterized by progressive loss of skeletal muscle mass and strength, combined with impaired physical function, is associated primarily with aging but also driven by chronic inflammation, immobility, and endocrine dysregulation. It leads to increased risks of...

🗓️ 2025-08-02
Read MorehUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.

Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics...

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (CC-MASLD) increases morbidity and mortality risk but has no aetiology-specific treatment. We investigated the safety and efficacy signals of severe energy restriction. In this randomised controlled trial, adults with CC-MASLD and...

🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSevere Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial.

Metformin has effects on multiple biological systems relevant to ageing and has been posited as a candidate therapy for sarcopenia and physical frailty. We aimed to test the efficacy and safety of metformin, a candidate geroprotector, to improve physical performance...

🗓️ 2025-03-24
Read MoreMetformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial.

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA-INT was to investigate whether BIO101 (20-hydroxyecdysone), an activator of the...

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-κB signaling and oxidative stress play...

🗓️ 2024-04-08
📰 Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!